Q-omics provides the consensus-scored ZNF681 profile across patient tissues and cancer cell-line models. ZNF681 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF681 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, ZNF681 RNA expression shows 19,786 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, LIHC, and THYM as cancer lineages where ZNF681 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF681 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF681 survival associations across molecular data types. ZNF681 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF681 RNA expression–survival associations across cancer types. High ZNF681 expression shows unfavorable associations in KICH and LIHC, but favorable associations in KIRC, UVM, UCS and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF681 RNA expression.
This table summarizes ZNF681 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF681. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF681 shows lower tumor expression in HNSC and READ and higher tumor expression in LIHC, BLCA, BRCA and LUAD. The LIHC box plot shows higher ZNF681 RNA expression in tumor versus normal tissue (log2 FC = +0.637, t-test p < 0.001).
This table shows molecular features associated with ZNF681 in patient tissues and cancer cell lines. In patient samples, ZNF681 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF681 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LARGE_INTESTINE.
